CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
大 B 细胞淋巴瘤中的 CAR-T 细胞疗法
英文原题：CAR T-cell therapy in large B cell lymphoma.
查看英文原题
CAR T-cell therapy in large B cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19靶向嵌合抗原受体（CAR）T细胞已经彻底改变了淋巴系统恶性肿瘤的治疗，包括大B细胞淋巴瘤（LBCL）。继2017年至2020年间发表的早期多中心临床试验之后，三种CD19-CAR-T 细胞产品在淋巴瘤三线治疗中获得FDA和EMA批准，为二线治疗的后续研究铺平了道路。与此同时，CAR-T 细胞疗法的应用研究进一步扩展至在一线常规化学免疫治疗完成前即治疗高危患者。此外，由于早期试验排除了伴有中枢神经系统淋巴瘤受累的患者，近期多项研究显示CD19-CAR-T 细胞在原发性和继发性CNS淋巴瘤中具有良好的疗效。本文详细概述了支持在LBCL患者中使用CAR-T 细胞的临床数据。
展开英文摘要原文
CD19-targeted chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19-CAR T-cell products received FDA and EMA approval designations in lymphoma in the third-line setting, paving the way for follow-up studies in the second-line.
Meanwhile, investigations into the applications of CAR T-cell therapy have further broadened to treating high-risk patients even prior to completion of first-line conventional chemo-immunotherapy.
Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19-CAR T-cells in primary and secondary CNS lymphoma.
Here we provide a detailed overview on clinical data supporting the use of CAR T-cells in patients with LBCL.
论文信息
- 作者
- Boardman AP、Salles G
- 单位
- Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, USA.United States
- 文献类型
- 综述
- 期刊
- Hematological oncology2023 Jun
- 原文标识
- PubMed 37294963 · DOI 10.1002/hon.3153
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →